Remove 2025 Remove Disease Remove Therapies
article thumbnail

Eli Lilly to Buy Gene Therapy Firm Verve in $1 Billion Deal to Develop Heart Drug

Drugs.com

WEDNESDAY, June 18, 2025 — Drugmaker Eli Lilly plans to buy Verve Therapeutics, a gene-editing startup, for about $1 billion upfront. The deal gives Lilly a potential new treatment for heart disease, The Wall Street Journal reported.

Therapies 173
article thumbnail

How AI will reshape pharma by 2025

Drug Target Review

Looking ahead, 2025 could represent a major turning point for the pharmaceutical sector. Their work focuses on creating ‘digital twin generators’ – AI-driven models that predict how a patients disease may progress over time. Approaches that improve data efficiency will drive this space, Smith explains.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How GPCR-targeting therapies are advancing the fight against inflammatory disease

Drug Target Review

Targeting GPCRs to fight inflammatory diseases GPCR-targeting drugs are well known therapies for a range of disease types, including cardio-metabolic, central nervous system and endocrinological disorders.

Disease 59
article thumbnail

Scientists create next generation of tools in battle against brain disease

Broad Institute

Scientists create next generation of tools in battle against brain disease By Corie Lok May 21, 2025 Breadcrumb Home Scientists create next generation of tools in battle against brain disease The findings contained in eight studies could lead to targeted gene therapies for brain disorders.

Disease 72
article thumbnail

Q&A with Worldwide’s Rare Disease Experts: The Latest Innovations and Hopes for 2025

Conversations in Drug Development Trends

In preparation for World Orphan Drug Congress Europe, we interviewed Nathan Chadwick, Senior Director, Therapeutic Strategy Lead, Rare Disease, and Derek Ansel, MS, LCGC, Vice President, Therapeutic Strategy Lead, Rare Disease, to hear their insights into the current progress in rare disease research and their hopes for 2025.

Disease 52
article thumbnail

Therapeutic Oligos 2025 Keynote Speakers Announced

Elrig

It will also cover recent advancements in broadening their application, including innovative approaches to ensure their safety and efficacy, the use of targeted delivery to reach disease-relevant tissues as well as success stories in bringing therapeutic oligonucleotides to the clinic.

RNA 59
article thumbnail

Broad Institute and Bayer extend their cardiovascular alliance

Broad Institute

Broad Institute and Bayer extend their cardiovascular alliance By Leah Eisenstadt June 11, 2025 Breadcrumb Home Broad Institute and Bayer extend their cardiovascular alliance Partnership will continue with renewed focus on developing new cardiovascular therapies.

Disease 93